Impedimed Limited Announces Director’s Increased Shareholding

Impedimed Limited ( (AU:IPD) ) has issued an update.

Impedimed Limited announced a change in the director’s interest, as Fiona Bones acquired an additional 268,169 ordinary shares, increasing her total holdings to 1,774,399 shares. This acquisition was part of a compensation arrangement where shares were issued in lieu of 30% of her director fees for the quarter ended June 30, 2025, reflecting a strategic approach to align management interests with shareholder value.

The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.15 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.

More about Impedimed Limited

Impedimed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices and services. The company’s primary products are designed for the measurement and monitoring of fluid status and body composition, with a market focus on healthcare providers and patients requiring precise fluid management solutions.

Average Trading Volume: 2,702,662

Technical Sentiment Signal: Sell

Current Market Cap: A$103.4M

For a thorough assessment of IPD stock, go to TipRanks’ Stock Analysis page.